These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21154170)

  • 1. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.
    Jimenez-Solem E; Rasmussen MH; Christensen M; Knop FK
    Curr Opin Mol Ther; 2010 Dec; 12(6):790-7. PubMed ID: 21154170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes.
    Berra CC; Resi V; Mirani M; Folini L; Rossi A; Solerte SB; Fiorina P
    Pharmacol Res; 2020 Sep; 159():104996. PubMed ID: 32574827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
    Gallwitz B; Dagogo-Jack S; Thieu V; Garcia-Perez LE; Pavo I; Yu M; Robertson KE; Zhang N; Giorgino F
    Diabetes Obes Metab; 2018 Feb; 20(2):409-418. PubMed ID: 28817231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial.
    Tuttolomondo A; Cirrincione A; Casuccio A; Del Cuore A; Daidone M; Di Chiara T; Di Raimondo D; Corte VD; Maida C; Simonetta I; Scaglione S; Pinto A
    Cardiovasc Diabetol; 2021 Jan; 20(1):1. PubMed ID: 33397395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dulaglutide: the newest GLP-1 receptor agonist for the management of type 2 diabetes.
    Thompson AM; Trujillo JM
    Ann Pharmacother; 2015 Mar; 49(3):351-9. PubMed ID: 25565404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
    Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
    Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
    Kaneko S; Oura T; Matsui A; Shingaki T; Takeuchi M
    Endocr J; 2017 Dec; 64(12):1165-1172. PubMed ID: 28904247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8).
    Dungan KM; Weitgasser R; Perez Manghi F; Pintilei E; Fahrbach JL; Jiang HH; Shell J; Robertson KE
    Diabetes Obes Metab; 2016 May; 18(5):475-82. PubMed ID: 26799540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
    Tanaka K; Okada Y; Tokutsu A; Tanaka Y
    Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
    Mari A; Del Prato S; Ludvik B; Milicevic Z; de la Peña A; Shurzinske L; Karanikas CA; Pechtner V
    Diabetes Obes Metab; 2016 Aug; 18(8):834-9. PubMed ID: 27059816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of once-weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD-2 clinical trial.
    Giorgino F; Yu M; Haupt A; Milicevic Z; García-Pérez LE
    Diabetes Obes Metab; 2019 Nov; 21(11):2570-2575. PubMed ID: 31364266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study.
    Sanada J; Kimura T; Shimoda M; Tomita A; Fushimi Y; Kinoshita T; Obata A; Okauchi S; Hirukawa H; Kohara K; Tatsumi F; Nakanishi S; Mune T; Kaku K; Kaneto H
    Front Endocrinol (Lausanne); 2021; 12():714447. PubMed ID: 34484124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. dulaglutide (Trulicity°) weekly in type 2 diabetes: Cardiovascular reactions should be better documented.
    Prescrire Int; 2016 Oct; 25(175):236-237. PubMed ID: 30645827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of once weekly dulaglutide by baseline beta-cell function in people with type 2 diabetes in the AWARD programme.
    Mathieu C; Del Prato S; Botros FT; Thieu VT; Pavo I; Jia N; Haupt A; Karanikas CA; García-Pérez LE
    Diabetes Obes Metab; 2018 Aug; 20(8):2023-2028. PubMed ID: 29603872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dulaglutide (LY-2189265) for the treatment of type 2 diabetes.
    Scheen AJ
    Expert Rev Clin Pharmacol; 2016; 9(3):385-99. PubMed ID: 26761217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.